Filing Flows › Vertex Pharmaceuticals (VRTX) › How it makes money
How Vertex Pharmaceuticals (VRTX) makes money
Vertex Pharmaceuticals (VRTX) made $3.4B of revenue in the third quarter 2026 (Q3 2026), +12% from a year earlier. Total CF product revenues, net brought in $3.3B (95%); CASGEVY brought in $99.2M (3%); JOURNAVX brought in $58.3M (2%). Of every dollar of revenue, 21¢ was left as operating profit, 19¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Total CF product revenues, net | $3.3B | 95.4% | +2% | +8% |
| ↳ TRIKAFTA/KAFTRIO | $2.4B | 71.0% | -2% | -8% |
| ↳ ALYFTREK | $706M | 20.6% | +23% | +186% |
| ↳ Other CF product revenues | $130M | 3.8% | -5% | -6% |
| CASGEVY | $99.2M | 2.9% | +30% | +487% |
| JOURNAVX | $58.3M | 1.7% | +18% | +197% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $3.4B | 100.0% |
| Operating profit | $713M | 20.8% |
| Income tax | $130M | 3.8% |
| Net earnings | $654M | 19.1% |
| Operating cash flow | $643M | 18.7% |
| Free cash flow | $546M | 15.9% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $3.4B | +12% |
| Q2 2026 | $3.3B | +12% |
| Q1 2026 | $3.0B | +8% |
| Q4 2025 | $3.2B | +10% |
| Q3 2025 | $3.1B | +11% |
| Q2 2025 | $3.0B | +12% |
| Q1 2025 | $2.8B | +3% |
From Vertex Pharmaceuticals' 10-Q filed Nov 3, 2026 (on EDGAR).
Questions
How does Vertex Pharmaceuticals make money?
Vertex Pharmaceuticals (VRTX) made $3.4B of revenue in the third quarter 2026 (Q3 2026), +12% from a year earlier. Total CF product revenues, net brought in $3.3B (95%); CASGEVY brought in $99.2M (3%); JOURNAVX brought in $58.3M (2%). Of every dollar of revenue, 21¢ was left as operating profit, 19¢ was left as net earnings.
What is Vertex Pharmaceuticals' biggest business?
Total CF product revenues, net: $3.3B in the third quarter 2026, 95% of revenue, +8% from a year earlier.
What is Vertex Pharmaceuticals' profit margin?
Net earnings were $654M, 19.1% of revenue, in the third quarter 2026; the operating margin was 20.8%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.